However, our results, suggesting a lower risk of invasive breast cancer among glucocorticoids users, especially for ER+ tumours, are supported by experimental models showing that the expression of the glucocorticoid receptor was correlated with improved breast cancer prognosis especially for ER+ tumours and that activation of the glucocorticoid receptor may reduce oestrogen-induced cell proliferation in ER+ breast cancer [19, 20]. The gene discussed is NR3C1; the disease is neoplasm.